Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Multiple Myeloma 3Leukemia, Plasma Cell 3Plasmacytoma 2Paraproteinemias 2Preleukemia 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine 3filanesib 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Dexamethasone 2Bortezomib 2Alemtuzumab 2ofatumumab 1fludarabine phosphate 1Zoledronic Acid 1Whole-Body Irradiation 1Stem Cell Transplantation 1Proteasome Inhibitors 1Mycophenolic Acid 1Lenalidomide 1KW-2478 1Hsp90 inhibitor KU757 1Denosumab 1Cyclophosphamide 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1CLR1404 1Busulfan 1Blood Cell Count 1ARQ531 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Paraproteinemias × filanesib × Other hematologic neoplasm × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡